Breaking News, Collaborations & Alliances

Imbrium, TetraGenetics Enter Biologics Discovery Collaboration

Partnership will focus on development of novel biologic therapeutics for pain using TetraExpress

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Imbrium Therapeutics, a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, and Tetragenetics, a biotech developing novel therapeutics for pain indications and autoimmune diseases, have formed a research and development collaboration to use TetraGenetics’ antibody discovery technology platform, TetraExpress, in the discovery and development of non-opioid biologic therapies for the treatment of chronic pain.   Imbrium will leverage TetraGenetics’ TetraExpress syste...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters